Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether trauma-focused treatments maintain efficacy in the clinically common scenario of concurrent cannabis and PTSD, addressing a critical knowledge gap that has led some clinicians to withhold evidence-based interventions from this population. Understanding treatment response patterns across cannabis use status directly informs risk-benefit decision-making and treatment selection for patients with comorbid PTSD and substance use disorders, who currently represent a significant proportion of individuals seeking mental health services.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis provides valuable evidence that trauma-focused cognitive behavioral therapy and prolonged exposure remain efficacious for PTSD even in the context of concurrent cannabis use, several important caveats warrant careful interpretation. The analysis draws from only four RCTs nested within a larger dataset, which limits statistical power and may not capture the heterogeneity of cannabis use patterns, potency profiles, or dosing frequencies that characterize real-world patient populations. Additionally, the mechanism by which cannabis might interfere with trauma processing or therapeutic engagement remains incompletely understood, and unmeasured confounders such as motivation for treatment, trauma severity, or the specific timing of cannabis use relative to therapy sessions could influence outcomes in ways the current design cannot fully disentangle. From a clinical standpoint, these findings suggest that active cannabis use should not automatically disqualify patients from evidence-based trauma treatment, though providers should still address cannabis use directly within treatment planning, monitor for potential therapeutic interference, and consider whether modifying use patterns might optimize treatment response.